Chronic Lymphocytic Leukemia - Alberta Health Services

CLINICAL PRACTICE GUIDELINE LYHE-007
Version 2
(32) Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, et al. Fludarabine plus
cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic
leukemia. Blood 2006 Feb 1;107(3):885-891.
(33) O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ, et al. Results of the fludarabine and
cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 2001 Mar 1;19(5):1414-1420.
(34) Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, et al. Rituximab using a thrice weekly dosing
schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and
acceptable toxicity. J Clin Oncol 2001 Apr 15;19(8):2153-2164.
(35) National Comprehensive Cancer Network. Non-Hodgkin’s lymphomas. Version V.1.2010. 2010; Available at:
http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf. Accessed 02/04, 2010.
(36) Byrd JC, Stilgenbauer S, Flinn IW. Chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program
2004:163-183.
(37) Byrd JC, Rai K, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE, et al. Addition of rituximab to fludarabine
may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic
leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005 Jan
1;105(1):49-53.
(38) Wierda GW, O’Brien S, Faderl S, Ferrajoli A, Koller C, Estrov Z, et al. CFAR, an active frontline regimen for highrisk
patients with CLL, including those with del 17p. Blood (ASH Annual Meeting Abstracts) 2008
Nov;112(11):Abstract 2095.
(39) Foon KA, Boyiadzis M, Land SR, Marks S, Raptis A, Pietragallo L, et al. Chemoimmunotherapy with low-dose
fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic
leukemia. J Clin Oncol 2009 Feb 1;27(4):498-503.
(40) Kay NE, Geyer SM, Call TG, Shanafelt TD, Zent CS, Jelinek DF, et al. Combination chemoimmunotherapy with
pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in
previously untreated B chronic lymphocytic leukemia. Blood 2007 Jan 15;109(2):405-411.
(41) Faderl S, Wierda W, O'Brien S, Ferrajoli A, Lerner S, Keating MJ. Fludarabine, cyclophosphamide, mitoxantrone
plus rituximab (FCM-R) in frontline CLL